Stung by intense criticism of its past penchant for secrecy and data manipulation, GlaxoSmithKline ($GSK) CEO Andrew Witty today took the transparency pledge, vowing to shine a light on all trial results--good and bad. GSK will also welcome outside investigators into its data vaults and offer some 200 potential tuberculosis-fighting compounds for public use. Report